Category: ALK Positive News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Groups Award Two Grants for ALK-positive Lung Cancer Research
(December 28, 2022) – ALK Positive Inc. (ALK Positive) and The Lung Cancer Research Foundation (LCRF) announce funding of two ALK-positive related lung cancer projects. These grants, totaling $500,000, are awarded to researchers whose projects are focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). “This is an…
-
Moderna’s Cancer Vaccine Program
Highly successful Covid vaccines have raised the question of ‘why not cancer vaccines?’, a question of great interest and financial contribution for the ALK Positive NSCLC community in recent years. Somewhat under the radar of our members is Moderna, Inc.’s multi-cancer clinical trial for their personalized mRNA vaccine that started in 2017. The trial is…
-
WE NEED YOUR INFO: Take part in our longitudinal survey of ALK+ Cancer Patients
More participants = more data = better research = more life!We invite you to complete a patient survey/registry specific to ALK-positive lung cancer. This is an IRB approved professionally study conducted by researchers at University of Washington and paid for by ALK Positive Inc. All data is de-identified, and will inform oncologists, researchers, patients and…
-
ALK+ Summit 2022 in Denver, CO was largest Summit yet!!
Date: July 29th-31st Attendees: in-person: 250 Virtual: 850 The ALK Positive annual summit was once again a huge success! This year the event was held both in Denver, Colorado and virtually (online). We had 250 individual registrations in-person and 850 virtual attendees. Our ALK Summit in Denver was a great opportunity to…
-
Dr. Kenneth Culver named Director of Research & Clinical Affairs for ALK Positive Inc.
We are excited to welcome Dr. Kenneth Culver as our first Director of Research & Clinical Affairs! Dr. Culver graduated from the University of Iowa College of Medicine in 1981. He completed his internship and residency in Pediatrics and a fellowship in Pediatric immunology at the University of California, San Francisco. At UCSF, he developed…
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem that we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two known mechanisms of resistance so far. One is for the cancer cells to activate an alternative bypass pathway such as EGFR, cMET, KRAS, or AXL…
-
The Latest & Greatest from ALK Positive Inc.
ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from the ALK Positive Support Group, all ALK-positive patients, and/or caregivers. The Board, Committees, and our CEO, are working together to improve the life expectancy and…
-
ALK Positive Inc. at ASCO (June 3-7, 2022)
“Going to ASCO was a great opportunity to network and represent the organization, help move ALK to the top, and let people know who we are. I feel it was a productive conference, and we look forward to continuing better relationships with everyone. As a patient-led organization, it is important for us that they see…
-
The latest from ALK Positive Inc.
May 14, 2022 ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from the ALK Positive Support Group, all ALK-positive patients, and/or caregivers. The Board, Committees, and our CEO, are working together to improve the…
-
LUNGevity Partners with ALK Positive to Award $1.5 Million in Lung Cancer Research Grants
FOR IMMEDIATE RELEASEMedia ContactColin Bartonmedical@alkpositive.org303-204-3388 WASHINGTON, DC (January 27, 2022) — LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the ALK-Positive Lung Cancer Research Award Program. This year, the patient oncogene group will potentially fund research projects totaling up to $1.5 million over two years—their…
-
$7.6M Gift Launches New Lung Cancer Research Initiative at University of Michigan’s Rogel Cancer Center
EDITOR’S NOTE: This is a reprint of a press release from the University of Michigan’s Rogel Cancer Center – this $7.6 million gift from Judith L. Tam and the Richard Tam Foundation may be the largest made to-date specifically for ALK-positive research. The direct link to the release is here: Increased understanding of the genetic…